Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Harvard Business School
Merck
Boehringer Ingelheim
Moodys

Last Updated: February 26, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR INDOXIMOD


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Indoximod

Trial ID Title Status Sponsor Phase Summary
NCT00567931 1-Methyl-D-Tryptophan in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery Completed National Cancer Institute (NCI) Phase 1 This phase I trial is studying the side effects and best dose of 1-methyl-D-tryptophan in treating patients with metastatic or refractory solid tumors that cannot be removed by surgery. Biological therapies, such as 1-methyl-D-tryptophan, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by stimulating the immune system.
NCT00739609 IDO Inhibitor Study for Relapsed or Refractory Solid Tumors Terminated NewLink Genetics Corporation Phase 1 This study provides an early evaluation of an entirely new class of small molecule agents directed at disruption or elimination of tumor tolerance, a phenomenon now demonstrated to be involved in the growth of many solid tumors.
NCT01042535 Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer Active, not recruiting National Cancer Institute (NCI) Phase 1/Phase 2 This randomized phase I/II trial studies the side effects and best dose of vaccine therapy and to see how well it works when given together with 1-methyl-D-tryptophan (1-MT) in treating patients with metastatic breast cancer. Vaccines made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells.
NCT01042535 Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer Active, not recruiting H. Lee Moffitt Cancer Center and Research Institute Phase 1/Phase 2 This randomized phase I/II trial studies the side effects and best dose of vaccine therapy and to see how well it works when given together with 1-methyl-D-tryptophan (1-MT) in treating patients with metastatic breast cancer. Vaccines made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells.
NCT01191216 1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors Completed National Cancer Institute (NCI) Phase 1 This phase I trial is studying the side effects and best dose of giving 1-methyl-d-tryptophan and docetaxel together in treating patients with metastatic solid tumors. Biological therapies, such as 1-methyl-d-tryptophan, may stop the growth of tumor cells by stimulating the immune system and by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving 1-methyl-d-tryptophan with chemotherapy may kill more tumor cells.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for Indoximod

Condition Name

Condition Name for
Intervention Trials
Unspecified Adult Solid Tumor, Protocol Specific 3
Glioma 2
Medulloblastoma 2
Glioblastoma Multiforme 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for
Intervention Trials
Glioma 3
Glioblastoma 3
Brain Neoplasms 3
Breast Neoplasms 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Indoximod

Trials by Country

Trials by Country for
Location Trials
United States 57
Poland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for
Location Trials
Georgia 8
Florida 5
Pennsylvania 4
Virginia 4
Iowa 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Indoximod

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 2/Phase 3 1
Phase 2 2
Phase 1/Phase 2 6
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Recruiting 6
Completed 3
Not yet recruiting 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Indoximod

Sponsor Name

Sponsor Name for
Sponsor Trials
NewLink Genetics Corporation 10
National Cancer Institute (NCI) 3
H. Lee Moffitt Cancer Center and Research Institute 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 10
NIH 3
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Medtronic
McKinsey
McKesson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.